Ladies and gentlemen, good morning. My name is Abby. I will be your conference operator today. At this time, I would like to welcome everyone to the conference call. Today's conference is being recorded. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press the star key followed by one on your telephone keypad. If you would like to withdraw your question, press star- one a second time. Thank you. I will now turn the conference over to Tom McCourt, Chief Executive Officer. You may begin. Thanks, Abby, and good afternoon, everyone. I'm Tom McCourt, Chief Executive Officer at Ironwood Pharmaceuticals, and I'm delighted that you've joined us today as we take you through this exciting announcement in our agreement to acquire VectivBio. Before I continue, please take a moment to review our Safe Harbor statement on slide 2. Joining me today are Sravan Emany, Ironwood's Chief Financial Officer, Michael Shetzline, our Chief Medical Officer, Andrew Davis, our Chief Business Officer, and following our remarks, we will open the call with a question-and-answer session. As was highlighted in our press release issued earlier this morning, Ironwood is entering into a definitive agreement to acquire VectivBio, which on close of the transaction, will expand our GI portfolio and further strengthen our position to become the leading GI healthcare company. VectivBio is a Switzerland-based clinical-stage biopharmaceutical company. We've been long admiring VectivBio because of their focus on developing treatments for severe rare conditions with high unmet medical need, including short bowel syndrome with intestinal failure. This acquisition fits squarely within our previously defined strategic framework, and we believe it represents a critical step for Ironwood to achieve our vision and deliver value to our patients and shareholders. There are several reasons we believe that this is the right transition for Ironwood today. The addition of VectivBio establishes Ironwood as a fully integrated biopharma with a leading commercial product in LINZESS and a strong pipeline for future growth with several key development milestones over the next 12 months. VectivBio's lead asset, apraglutide, is a potential best-in-class GLP-2 analog that we believe is highly differentiated and, if successfully developed and approved, poised to become the standard of care in the treatment of short bowel syndrome with intestinal failure, a disease which there is considerable unmet medical need. We have high conviction for apraglutide's clinical program based on the mechanism of action, the enhanced potency, the extended half-life, the unique convenience of weekly dosing, and the compelling data to date. We believe Ironwood is best positioned to maximize the potential value of apraglutide for patients and shareholders by leveraging our expertise in clinical development, regulatory, medical affairs, and commercial execution, as evidenced by the blockbuster success we've had with Linzess. Short bowel syndrome with intestinal failure is primarily treated by gastroenterologists, where we have a strong network that we've built over the past decade. We believe that there will be a significant opportunity to drive significant operating leverage through Ironwood's existing commercial capabilities to support the potential commercial launch if approved. Finally, we believe the acquisition creates an attractive financial profile in the long- term, with apraglutide providing significant catalyst to extend Ironwood's growth horizon and the potential to deliver sustained profits and cash through the 2030s. On slide 5, you can see the expanded development portfolio created through this acquisition. We have several exciting clinical data and regulatory milestones expected this year. First, we have an upcoming June PDUFA date for the potential Linzess functional constipation indication in children and adolescents ages 6 to 17 years old. Second, we expect early data from CNP-104 for the potential treatment of primary biliary cholangitis in the second half of the year. Finally, with apraglutide, we expect the top-line phase III readout by the end of the year for the potential treatment of short bowel syndrome with intestinal failure. We're particularly excited about our pipeline that now includes multiple highly innovative clinical stage assets, including apraglutide and CNP-104. We believe both have the potential to address a significant unmet medical need and, if successfully developed and approved, can redefine standard of care for patients suffering from short bowel syndrome with intestinal failure as well as PBC, respectively. I'll turn it over to Mike. Thanks, Tom. I'm excited to talk to you about a potential new standard of care for patients suffering from short bowel syndrome with intestinal failure. SBS-IF is a severe organ failure condition where the small bowel is not able to keep up with the fluid and nutritional requirements of the body, which may require lifelong parenteral support. SBS-IF is associated with increased mortality, significant morbidity, high economic burden, and reduced quality of life. Patients with the most severe SBS-IF may require parenteral support infusions for up to 10-15 hours per day, often seven days a week. This condition impacts approximately 18,000 adult patients across the United States, Europe, and Japan. There's a considerable need in this patient population for therapeutic options that ideally aim to help provide enteral autonomy. Enteral autonomy is getting the patient back to the state where the small bowel is able to keep up with their metabolic needs, and the patient no longer requires parenteral support. Moving to slide 8, there are three key reasons why we believe that apraglutide has the potential to be best in class and the new standard of care in SBS-IF. First, apraglutide is a GLP-2 analog designed for enhanced potency, selectivity, and to be longer-acting versus other GLP-2s. Second, the ongoing phase III study has been designed to evaluate efficacy in both SBS-IF patient populations, stoma and colon-in-continuity. Third, apraglutide has the potential for differentiated convenience of weekly dosing versus other GLP-2 therapies. In summary, we have a high level of conviction in apraglutide's clinical program based on its mechanism of action, it's designed for enhanced potency, selectivity, and extended half-life, as well as compelling data to date. We're looking forward to the top-line results of the STARS-3, phase III, expected by the end of this year. With that, I'll now turn the presentation back to Tom. Thanks, Mike. I'd like to spend a few minutes framing the apraglutide commercial opportunity in short bowel syndrome with intestinal failure. As I mentioned earlier, we believe apraglutide has the potential to achieve $1 billion in peak net sales and significantly expand the treated patients in SBS with intestinal failure based on this unique product profile Mike just outlined. For reference, GATTEX, the first generation GLP-2, is the SBS with intestinal failure is indicated for intestinal failure, reported roughly $750 million in net sales in 2022. We believe the potential to address the stoma and colon-in-continuity population, combined with the convenient once-weekly dosing, presents the opportunity to potentially decrease the days on parenteral support and achieve greater sales success versus other GLP-2s. There is the potential to expand use outside the United States as Ironwood retains the optionality for ex-U.S. commercial strategy moving forward. Slide 11 shows many similarities between apraglutide and Ironwood's GI portfolio today. We believe Ironwood is the right company to continue to lead apraglutide through the development and potential approval. Ironwood, as a leading commercial, regulatory, and clinical development capabilities, given our significant focus and expertise in GI and our deep relationships across the GI community. This acquisition has the potential to enhance our GI portfolio, which now includes a blockbuster marketed product in Linzess, which continues to deliver impressive demand growth, a phase II asset in CNP-104, and upon close of the transaction, a phase III clinical asset in apraglutide. We believe all three of these assets represent opportunities that have the potential to advance standard of care for GI patients and position us well for future growth. I now would like to turn the call over to Shravan, who's going to review the transaction details and financial. Thanks, Tom. The addition of VectivBio and the commercial launch potential for apraglutide provides additional near-term revenue potential with a line of sight for Ironwood to replace revenues attributable to LINZESS by its 2029 patent expiration. It provides long-term revenue and profit growth potential through the 2030s. We believe that apraglutide, if approved, has the potential to reach $1 billion in net sales in short bowel syndrome with intestinal failure and represents a highly synergistic opportunity with our existing commercial capabilities in GI. Apraglutide and CNP-104 provide Ironwood with two exciting assets for the treatment of rare GI diseases with potential for combined peak net sales of greater than $1.5 billion. On slide 14, I'll review the key transaction terms. Pursuant to the terms of the transaction agreement, Ironwood will commence a tender offer to acquire all outstanding shares of VectivBio for $17 per share in cash, which represents aggregate consideration approximately $1 billion. In conjunction with this transaction, Ironwood will have access to a new $500 million four-year revolving credit facility. We expect to fund this transaction through a combination of cash on hand and drawn funds on the new facility. We anticipate this transaction will close in the second half of 2023, subject to satisfaction of all closing conditions, including HSR approval and the valid tender of at least 80% of all VectivBio shares. We expect to provide updated full year 2023 adjusted EBITDA guidance upon closing of the transaction. Moving forward, we continue to maintain our focus on generating sustained profits and meaningful cash flows while potentially extending our growth horizon through the 2030s. Ironwood expects to generate greater than $175 million in operating cash flows each year on a pro forma basis ahead of a potential apraglutide commercial launch. We expect the transaction to be accretive to earnings per share beginning in 2026, and we expect adjusted EBITDA to return to greater than $250 million by the end of 2025. We anticipate being able to realize significant operating leverage with the addition of apraglutide and the overlap of Ironwood's existing commercial and development capabilities in GI. Ironwood anticipates total net debt to EBITDA of roughly 3 x at closing, and we expect cash flows from Linzess will support a rapid delevering to below 2 x total net debt to EBITDA ahead of a potential apraglutide commercial launch in 2025. Moving forward, we will continue to prioritize investments to maximize the value of Linzess, progress apraglutide and CNP-104 towards commercialization, and manage our capital structure through debt paydown, while maintaining the flexibility to evaluate additional opportunities for capital deployment. To wrap up, today's announcement is an exciting step forward as we continue to strengthen our position to become the leading GI healthcare company. It represents an opportunity to accelerate Ironwood's growth well beyond Linzess LOE, while providing innovative treatments for GI patients. We believe that Ironwood is best positioned to maximize the full potential of apraglutide because of our GI expertise and capabilities. Both CNP-104 and apraglutide represent exciting opportunities with the potential to deliver significant value to patients, physicians, and shareholders. We look forward to collaborating with the talented and hardworking VectivBio team. Together, we can advance important research and clinical development in serious, rare GI diseases and develop apraglutide to address unmet needs in short bowel syndrome with intestinal failure. Our shared expertise, passion, and promising pipelines will greatly expand the reach of our public health contributions and the impact we can make on patient lives and create value for all our stakeholders. Operator, you may now open up the line for questions. Operator? My apologies. I was on mute. I would like to remind everyone, if you would like to ask a question, press star, then one on your telephone keypad. We will pause for just a moment to compile the Q&A roster. We will take our first question from David Amsellem with Piper Sandler. Your line is open. Thanks, quite transformative. A couple of questions. First, as you were vetting apraglutide, how are you thinking about the competitive landscape? Particularly wanted to pick your brain on glepaglutide, and also the GLP-1, dapiglutide, and how are you thinking about those agents vis-a-vis apraglutide? That's number one. Number two, understood that GATTEX certainly has its limitations, but in the not-too-distant future, it is going to lose exclusivity. I guess with that in mind, you know, how are you thinking about pricing? Help us understand your assumptions here. Maybe it's too soon to ask, but figured I'd give it a shot. Thanks. Thanks, David. I'll let Tom answer the first part of the question, and then Andrew Davis will answer the second part. Thanks, David. You know, obviously, this is a tremendous opportunity for us. I think you're very familiar with short bowel syndrome, with intestinal failure. This is a very debilitating disease. You know, while GATTEX was certainly a step forward, it, as you mentioned, has a lot of limitations with regard to daily dosing, its potency, its effect across you know, the spectrum of patients. When we looked at apraglutide, you know, we clearly see this as a potential best-in-class agent. You know, it has clearly enhanced potency. You know, the once weekly dosing versus daily dosing is a tremendous advancement. Of course, the clinical data we've seen to date with regard to its efficacy is really quite stunning. I think, you know, that profile versus the other GLP-2s, it clearly stands out on its own. I think, you know, we're very excited to move forward with it. As far as some of our thoughts as far as go-to-market strategy and pricing, I'm going to have Andrew maybe address that. Andrew? Yeah, thanks. I think it is a little early for us to comment or guide on pricing at this point. You know, we closed or signed this late last night. I think we'll provide an update on that as we roll forward with our commercial activities going forward. Okay, that's helpful. If I might just sneak in, a quick follow-up just for my own edification regarding the market? Are you thinking over the commercial life of the product that this is going to be just a product that will be used just on patients on parenteral support, or are there patients with short bowel who are not on parenteral support where this could also be an audience over time? Thank you. Mike? Yeah, thanks, David. It's a good question. The main mechanism of action, as you know, for the GLP-2 class rests in restoring sort of the gut lining or the epithelium. That provides the enhanced absorptive capacity, which gives the main clinical benefit, which is enhanced fluid absorption and nutrient absorption. From that capacity, it really does fit best with patients requiring parenteral support because parenteral support is when you have to take nutrients and fluid that you can't get orally by another route, the parenteral route or IV. I think it lends itself best to that. There certainly are a subgroup of patients with short bowel syndrome who don't necessarily need parenteral support, but I think the more relevant cohort is the patient population who don't require greater than three days per week of parenteral support. There is a group of short bowel syndrome, intestinal failure patients who only need one or two days a week. They're not currently in the phase two program, to be clear, but they are a relevant population in terms of requiring parenteral support who would be, I think, a group that we should think very strongly about the utility of a once weekly therapy for that patient population. Okay, that's helpful. Thanks. We will take our next question from Tim Chiang with Capital One Securities. Your line is open. Hi, thanks. Could you talk a little bit about, you know, the differences with apraglutide, especially in the CIC treatment population? It seems like, you know, the company had shown some positive data in just that subpopulation. Can you talk a little bit about the significance of that? Yes. Mike, why don't you respond to that? Sure, sure. It is a really important question because as you know, and historically, the relevance is that the GLP-2s as they've moved through, you know, commercial use, and obviously we're talking about GATTEX in this setting, the clinical development program really didn't show a benefit in the colon-in-continuity population. The primary benefit was derived from the stoma population. The reason for that is, the primary output was really parenteral support volume and based on urinary output. The VectivBio development team really did a great job, I think, in terms of the development program design to really tease that out and work with that to look at how to better address the colon-in-continuity population because it is different. Physiologically, it's different. We know factually that the colon sits there primarily to absorb fluid. It certainly does other activities, don't get me wrong, but the colon does, in some ways, function as a big nephron and absorb fluid. They clearly have a different way of managing fluid in a good way for patients who need parenteral support but have a colon. Their deficit is primarily around nutrients, not necessarily volume. What the development team of VectivBio did was they instituted a unique what they call weaning algorithm that allows those patients to be managed differently through the clinical trial. Still, urinary output is a key factor in determining the parenteral support volumes, but the other aspects of their physiology are also taken into consideration, including their nutrient status, caloric intake, stool form, and frequency in those entities. In the STARS phase III, they actually instituted that design to better tease out the clinical benefit in colon-in-continuity patients. We think that's a huge advantage in likely potentially differentiating and leading us potentially to this best-in-class standard of care for short bowel syndrome with intestinal failure. The study you're alluding to, the nutrition study, has already demonstrated a very robust clinical benefit in colon-in-continuity patients. It really is the first wet approach in that regard for a weekly therapy to demonstrate this level of clinical benefit in colon-in-continuity patients. Mike, maybe just one follow-up on apraglutide. You know, obviously, there's a slightly different PK profile with apraglutide versus the existing products on the market. Can you talk a little bit about the significance of that and also the half-life? Yeah. What profile? PKPD. Oh, apraglutide. Oh, PKPD. Yeah, sorry. I missed the PKPD. Sorry. Thanks for the clarification. I think the key real physiology or pharmacology behind apraglutide is the fact that it is a more potent and more selective GLP-2. This really allows for its extended half-life or provides its extended half-life, and then gives us the opportunity or provided VectivBio obviously on the front end, the opportunity for weekly dosing. It is, and it's been looked at in preclinical studies quite extensively comparing to the other GLP-2 agents. It really does have very robust superiority in terms of at the preclinical level on selectivity and potency. Mike, maybe you can comment on the contrast of the half-life of apraglutide versus, you know, GATTEX. Yeah, sure. The, the native peptide, right, the thing in the body is really, half-life is on the order of minutes. GATTEX obviously made strides in that regard by having a half-life of 2 hours. That's why it had to have a daily dosing. Apraglutide really gets into the spectrum of a 70-hour half-life, which provides for the weekly opportunity from a convenience perspective. Okay. No, that's very helpful. Do you think that there would be any difference in side effects at all versus teduglutide with apraglutide? To date, obviously, we're following safety quite closely. We know the safety, obviously, from that class. There's been a lot of data out that from the other GLP-2s, including GATTEX. We certainly don't see any reason to be concerned from a safety perspective. I think the potency part is what gives us the opportunity to have a lot of exposure throughout the week on the receptors from an agonist perspective to provide the epithelial reconstitution of the regrowth necessary to improve the absorptive capability of small bowel. We think that's actually leaning more on the enhanced efficacy of provisions throughout the week. Okay. No, that's helpful. Thanks so much, Mike. As a reminder, it is star-one if you would like to ask a question. We will take our next question from Boris Peaker with Cowen. Your line is open. Great. Good morning. My first question is on the pivotal study readout later this year for apraglutide, what do you need to see in that data to support your $1 billion in peak sales thesis? Yeah, Mike, why don't you? Yeah. I think the key, the key feature, obviously, is the benefit in weekly parenteral support. I think that's the linchpin. Obviously, it's been the regulatory approved endpoint. It's certainly the endpoint that VectivBio worked with the agencies to agree upon. I think that's the main outcome. I think the nuances which provide an upside here and a unique feature for best-in-class reside around some of the other key endpoints that the VectivBio team has built into the clinical program. They really include the ability to look at stoma and CIC patients uniquely. And again, you know, the 24-week is the primary endpoint. That's obviously built in individually from the stoma patients. Critically, they're looking deeply at the colon-in-continuity benefit. As I mentioned earlier, using that weaning algorithm, there certainly is a reason to believe they can demonstrate improved outcomes in colon-in-continuity. Very importantly, there's an aspect to the design, including the statistical analysis, that will try to tease out the benefit for the colon-in-continuity patients around enteral autonomy. That's actually taking those patients and weaning them completely off parenteral support. That has happened, we know that the GLP-2s can achieve that. I think with the extended half-life and enhanced potency, as well as the clinical trial design, that's a unique opportunity for apraglutide, the VectivBio team really has championed that approach. Yeah. Boris, just a couple of initial thoughts as we've done obviously a good deal of market research on this as well as, you know, through our due diligence. You know, a couple things. You know, what we do see with GATTEX is there's a rapid or very low adherence rate, you know, over a year or two-year period of time. You know, roughly 50%, you know, discontinue within 12 months, almost 70% in year two. You know, what's driving that is really the lack of clinical benefit, one, with, you know, this broader population. Obviously having a, you know, more effective agent on a broader population obviously is gonna drive growth. I think the other thing that we fully expect is greater adherence. Now, there's certainly challenges with daily injections versus a once-a-week injection, but I think what's gonna really drive it is the overall efficacy of the drug, and I think that's what we're hoping to see, you know, and fully expect to see out of the clinical trial and the unique design. Yeah. Just to add to what Tom just said, that's the key feature of this enhanced opportunity around the CIC efficacy, because that will play into the primary endpoint for the total population. Just quick follow-up. your billion-dollar sales potential, does that assume that some of these patients are weaned off parenteral support in the study, or is that just upside that's not critical to your assumption? I mean, as far as we're looking at it, you know, we're looking at, you know, what is it gonna take to penetrate the market? You know, based on, you know, all the adoption work we've done with prescribers, you know, they really like, you know, the broad application. Certainly the weaning algorithm is obviously very attractive to say, you know, we can actually get people off parenteral nutrition, but also just the raw convenience of managing these patients, which is really difficult to manage these patients. It has obviously high morbidity and mortality. As I go back to our real premise on why we love this agent, it's really about this whole clinical profile, starting with potency and certainly convenience, but also, as was mentioned earlier, you know, the strength of the clinical data to date, which obviously is going to be predictive of what we hope to see in the phase III trial later this year. Great. Thanks for taking my question. Thanks, Boris. Ladies and gentlemen, this concludes today's conference call, and we thank you for your participation. You may now disconnect.